<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002054</url>
  </required_header>
  <id_info>
    <org_study_id>022C</org_study_id>
    <secondary_id>87-71 (Part C)</secondary_id>
    <nct_id>NCT00002054</nct_id>
  </id_info>
  <brief_title>A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients</brief_title>
  <official_title>A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fisons</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability, and description of time to Pneumocystis carinii
      pneumonia (PCP) for long-term biweekly administration of 1 of 2 doses of aerosol pentamidine
      when used as a prophylactic agent in patients who have had one episode of AIDS-associated
      PCP.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Pneumonia, Pneumocystis Carinii</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentamidine isethionate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients who have completed 16 treatments under Fisons study no. 87-71 entitled, &quot;A
        Double-Blind Group Comparative Study To Evaluate the Safety and Effectiveness of Three
        Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia
        in Patients With AIDS Post First Episode PCP.&quot; Detailed safety parameters must have been
        documented for 6 months.

          -  Patients must receive the first dose on this study within 2 weeks of their last dose
             under study no. 87-71.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following are excluded:

          -  Requiring ongoing active therapy for an opportunistic infection (O.I.) at time of
             entry or those patients with either of the following AIDS-defining O.I.'s at entry:

          -  Toxoplasmosis.

          -  Cryptococcosis.

          -  Pulmonary Kaposi's sarcoma.

          -  Asthma poorly controlled by medication.

          -  Receiving active therapy for tuberculosis.

        Patients with the following are excluded:

          -  Requiring ongoing active therapy for an opportunistic infection (O.I.) at time of
             entry or those patients with either of the following AIDS-defining O.I.'s at entry:

          -  Toxoplasmosis.

          -  Cryptococcosis.

          -  Pulmonary Kaposi's sarcoma.

          -  Unwilling to sign informed consent.

          -  Cannot cooperate with study procedures.

          -  Asthma poorly controlled by medication.

          -  Receiving active therapy for tuberculosis.

        Active substance abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fisons Corp</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hogan CH, Hodges JS, Mugglin A, Peterson PM, Abrams DI, Saravolatz L. The perils of visit-driven endpoints in antiretroviral trials. Int Conf AIDS. 1996 Jul 7-12;11(1):237 (abstract no TuB522)</citation>
  </reference>
  <reference>
    <citation>Wulfsohn M, Fischl M, Tsiatis A. Predictors of survival among patients with AIDS receiving zidovudine. Int Conf AIDS. 1992 Jul 19-24;8(2):C314 (abstract no PoC 4419)</citation>
  </reference>
  <reference>
    <citation>De Gruttola V, Wulfsohn M, Fischl MA, Tsiatis A. Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr. 1993 Apr;6(4):359-65.</citation>
    <PMID>8095980</PMID>
  </reference>
  <reference>
    <citation>Lavelle J, Murphy R, Harding P, Pierce P. Aerosolized pentamidine prophylaxis following Pneumocystis carinii pneumonia in patients with AIDS. Int Conf AIDS. 1990 Jun 20-23;6(2):374 (abstract no 2083)</citation>
  </reference>
  <verification_date>October 1989</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Pneumonia, Pneumocystis carinii</keyword>
  <keyword>Pentamidine</keyword>
  <keyword>Dose-Response Relationship, Drug</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentamidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

